Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2024

Open Access 01-12-2024 | Hypertension | Research

Evaluation of the prevalence of cardiometabolic disorders (diabetes, hypertension, and hyperlipidemia) diagnosed, undiagnosed, treated, and treatment goal in the elderly: Bushehr Elderly Health Program (BEH)

Authors: Mahbube Ebrahimpur, Erfan Mohammadi-Vajari, Yasaman Sharifi, Leila Ghotbi, Masoumeh Sarvari, Aryan Ayati, Baran Hashemi, Zhaleh Shadman, Pouria Khashayar, Afshin Ostovar, Noushin Fahimfar, Gita Shafiee, Elnaz Shahmohamadi, Tahereh Yavari, Iraj Nabipour, Bagher Larijani, Moloud Payab, Farshad Sharifi

Published in: BMC Endocrine Disorders | Issue 1/2024

Login to get access

Abstract

As the population ages, the global burden of cardiometabolic disorders will increase. This study aimed to investigate the prevalence of cardiometabolic disorders (diabetes, hypertension, and hyperlipidemia) in elderly and to evaluate the effects of various variables including age, sex, education, marital status, smoking, income, physical activity, dementia and depressed mood on untreated cardiometabolic disorders. This was a cross sectional study conducted in Bushehr Elderly Health Program. A total 2381 participants were included. Medical data were collected by trained interviewers. The mean age of the study participants was 69.34 years. Proportions of diabetes, hypertension, hyperlipidemia and hypercholesterolemia were 43.25%, 75.71%, 64.74% and 35.31% respectively. Untreated diabetes prevalence was higher for males (OR = 1.60, 95%CI = 1.20–2.15), older adults (OR = 1.02, 95%CI = 1.00–1.05), and pre-frail status (OR = 0.69, 95%CI = 0.52–0.92). Males (OR = 2.16, 95%CI = 1.64–2.84) and current smokers (OR = 1.42, 95%CI = 1.05–1.93), in contrast to married participants (OR = 0.25, 95%CI = 0.08–0.78), people with higher education levels (OR = 0.51, 95%CI = 0.29–0.89) and dementia (OR = 0.78, 95%CI = 0.61–1.00) were more likely to have untreated HTN. Untreated dyslipidemia is more common in smokers (OR = 1.78, 95%CI = 1.19–2.66) and males (OR = 1.66, 95%CI = 1.21–2.27), while untreated hypercholesteremia is more common in males (OR = 3.20, 95%CI = 1.53–6.69) and is reported lower in people with dementia (OR = 0.53, 95%CI = 0.28–1.01).
Literature
2.
go back to reference Cevenini E, et al. Age-related inflammation: the contribution of different organs, tissues and systems. How to face it for therapeutic approaches. Curr Pharm Des. 2010;16(6):609–18.CrossRefPubMed Cevenini E, et al. Age-related inflammation: the contribution of different organs, tissues and systems. How to face it for therapeutic approaches. Curr Pharm Des. 2010;16(6):609–18.CrossRefPubMed
3.
4.
go back to reference Taheri H, et al. Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial. J Diabetes Metabolic Disorders. 2023;22(2):1723–30.CrossRef Taheri H, et al. Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial. J Diabetes Metabolic Disorders. 2023;22(2):1723–30.CrossRef
5.
go back to reference Chai L, Xue J. Weight, weight perceptions, and Health and Well-being among Canadian adolescents: evidence from the 2017–2018 Canadian Community Health Survey. Am J Health Promot. 2022;36(1):55–63.CrossRefPubMed Chai L, Xue J. Weight, weight perceptions, and Health and Well-being among Canadian adolescents: evidence from the 2017–2018 Canadian Community Health Survey. Am J Health Promot. 2022;36(1):55–63.CrossRefPubMed
6.
go back to reference Sapra A, Bhandari P. Diabetes Mellitus, in StatPearls. 2022, StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.: Treasure Island (FL). Sapra A, Bhandari P. Diabetes Mellitus, in StatPearls. 2022, StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.: Treasure Island (FL).
7.
go back to reference Al Busaidi N, Shanmugam P, Manoharan D. Diabetes in the Middle East: government health care policies and strategies that address the growing diabetes prevalence in the Middle East. Curr Diab Rep. 2019;19(2):1–10.CrossRef Al Busaidi N, Shanmugam P, Manoharan D. Diabetes in the Middle East: government health care policies and strategies that address the growing diabetes prevalence in the Middle East. Curr Diab Rep. 2019;19(2):1–10.CrossRef
9.
go back to reference Turk-Adawi K, et al. Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden. Nat Reviews Cardiol. 2018;15(2):106–19.CrossRef Turk-Adawi K, et al. Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden. Nat Reviews Cardiol. 2018;15(2):106–19.CrossRef
10.
go back to reference Najafipour H, et al. Prevalence and incidence of pre-hypertension and hypertension (awareness/control) in Iran: findings from Kerman coronary artery diseases risk factors study 2 (KERCADRS). J Hum Hypertens. 2022;36(5):461–72.CrossRefPubMed Najafipour H, et al. Prevalence and incidence of pre-hypertension and hypertension (awareness/control) in Iran: findings from Kerman coronary artery diseases risk factors study 2 (KERCADRS). J Hum Hypertens. 2022;36(5):461–72.CrossRefPubMed
12.
go back to reference Asemu MM, et al. Prevalence and risk factors of Dyslipidemia among adults: A Community based study in Addis Ababa, Ethiopia. Am J Nurs. 2022;11(1):20–9. Asemu MM, et al. Prevalence and risk factors of Dyslipidemia among adults: A Community based study in Addis Ababa, Ethiopia. Am J Nurs. 2022;11(1):20–9.
13.
go back to reference Rosada A, et al. Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study. Lipids Health Dis. 2020;19(1):92.CrossRefPubMedPubMedCentral Rosada A, et al. Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study. Lipids Health Dis. 2020;19(1):92.CrossRefPubMedPubMedCentral
14.
go back to reference Grundy SM, et al. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med. 1999;159(15):1670–8.CrossRefPubMed Grundy SM, et al. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med. 1999;159(15):1670–8.CrossRefPubMed
15.
go back to reference Dornbrook-Lavender KA, Roth MT, Pieper JA. Secondary prevention of coronary heart disease in the elderly. Ann Pharmacother. 2003;37(12):1867–76.CrossRefPubMed Dornbrook-Lavender KA, Roth MT, Pieper JA. Secondary prevention of coronary heart disease in the elderly. Ann Pharmacother. 2003;37(12):1867–76.CrossRefPubMed
16.
go back to reference Shafiee G, et al. Bushehr Elderly Health (BEH) programme: study protocol and design of musculoskeletal system and cognitive function (stage II). BMJ Open. 2017;7(8):e013606.CrossRefPubMedPubMedCentral Shafiee G, et al. Bushehr Elderly Health (BEH) programme: study protocol and design of musculoskeletal system and cognitive function (stage II). BMJ Open. 2017;7(8):e013606.CrossRefPubMedPubMedCentral
17.
go back to reference Ebrahimpur M, et al. Osteoporosis and cognitive impairment interwoven warning signs: community-based study on older adults-Bushehr Elderly Health (BEH) Program. Arch Osteoporos. 2020;15(1):140.CrossRefPubMed Ebrahimpur M, et al. Osteoporosis and cognitive impairment interwoven warning signs: community-based study on older adults-Bushehr Elderly Health (BEH) Program. Arch Osteoporos. 2020;15(1):140.CrossRefPubMed
18.
go back to reference Sharifi F, et al. Studying the relationship between cognitive impairment and frailty phenotype: a cross-sectional analysis of the Bushehr Elderly Health (BEH) program. J Diabetes Metab Disord. 2021;20(2):1229–37.CrossRefPubMedPubMedCentral Sharifi F, et al. Studying the relationship between cognitive impairment and frailty phenotype: a cross-sectional analysis of the Bushehr Elderly Health (BEH) program. J Diabetes Metab Disord. 2021;20(2):1229–37.CrossRefPubMedPubMedCentral
19.
go back to reference Fleming GA, et al. Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care. 2020;43(1):250–60.CrossRefPubMed Fleming GA, et al. Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care. 2020;43(1):250–60.CrossRefPubMed
20.
go back to reference Health NI. ATP III guidelines at-a-glance quick desk reference. NIH publication, 2001: p. 01-3305. Health NI. ATP III guidelines at-a-glance quick desk reference. NIH publication, 2001: p. 01-3305.
21.
22.
go back to reference Esteghamati A, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National Survey of Risk factors for non-communicable diseases of Iran. Diabetes Care. 2008;31(1):96–8.CrossRefPubMed Esteghamati A, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National Survey of Risk factors for non-communicable diseases of Iran. Diabetes Care. 2008;31(1):96–8.CrossRefPubMed
23.
go back to reference Wild S, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.CrossRefPubMed Wild S, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.CrossRefPubMed
24.
25.
go back to reference Mone P, et al. Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study. Cardiovasc Diabetol. 2023;22(1):94.CrossRefPubMedPubMedCentral Mone P, et al. Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study. Cardiovasc Diabetol. 2023;22(1):94.CrossRefPubMedPubMedCentral
26.
go back to reference Mallappallil M, et al. Chronic kidney disease in the elderly: evaluation and management. Clin Pract (Lond). 2014;11(5):525–35.CrossRefPubMed Mallappallil M, et al. Chronic kidney disease in the elderly: evaluation and management. Clin Pract (Lond). 2014;11(5):525–35.CrossRefPubMed
27.
go back to reference Arabi T, et al. Obesity-related kidney disease: beyond hypertension and insulin-resistance. Front Endocrinol (Lausanne). 2022;13:1095211.CrossRefPubMed Arabi T, et al. Obesity-related kidney disease: beyond hypertension and insulin-resistance. Front Endocrinol (Lausanne). 2022;13:1095211.CrossRefPubMed
28.
go back to reference Muratsu J, et al. The combination of high levels of Adiponectin and insulin resistance are affected by aging in non-obese old peoples. Front Endocrinol (Lausanne). 2021;12:805244.CrossRefPubMed Muratsu J, et al. The combination of high levels of Adiponectin and insulin resistance are affected by aging in non-obese old peoples. Front Endocrinol (Lausanne). 2021;12:805244.CrossRefPubMed
29.
go back to reference Barrett KV, McCurley AT, Jaffe IZ. Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation. Clin Exp Pharmacol Physiol. 2013;40(12):902–9.CrossRefPubMedPubMedCentral Barrett KV, McCurley AT, Jaffe IZ. Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation. Clin Exp Pharmacol Physiol. 2013;40(12):902–9.CrossRefPubMedPubMedCentral
30.
go back to reference Gorini S, et al. Role of Aldosterone and Mineralocorticoid receptor in Cardiovascular Aging. Front Endocrinol (Lausanne). 2019;10:584.CrossRefPubMed Gorini S, et al. Role of Aldosterone and Mineralocorticoid receptor in Cardiovascular Aging. Front Endocrinol (Lausanne). 2019;10:584.CrossRefPubMed
31.
go back to reference Abboud M, Karam S. Hypertension in the Middle East: current state, human factors, and barriers to control. J Hum Hypertens. 2022;36(5):428–36.CrossRefPubMed Abboud M, Karam S. Hypertension in the Middle East: current state, human factors, and barriers to control. J Hum Hypertens. 2022;36(5):428–36.CrossRefPubMed
32.
go back to reference Amini M, et al. Socioeconomic inequalities in prevalence, awareness, treatment and control of hypertension: evidence from the PERSIAN cohort study. BMC Public Health. 2022;22(1):1–11.CrossRef Amini M, et al. Socioeconomic inequalities in prevalence, awareness, treatment and control of hypertension: evidence from the PERSIAN cohort study. BMC Public Health. 2022;22(1):1–11.CrossRef
33.
go back to reference Das SK, Sanyal K, Basu A. Study of urban community survey in India: growing trend of high prevalence of hypertension in a developing country. Int J Med Sci. 2005;2(2):70.CrossRefPubMedPubMedCentral Das SK, Sanyal K, Basu A. Study of urban community survey in India: growing trend of high prevalence of hypertension in a developing country. Int J Med Sci. 2005;2(2):70.CrossRefPubMedPubMedCentral
34.
go back to reference Pasdar Z, et al. Orthostatic hypertension and major adverse events: a systematic review and meta-analysis. Eur J Prev Cardiol. 2023;30(10):1028–38.CrossRefPubMed Pasdar Z, et al. Orthostatic hypertension and major adverse events: a systematic review and meta-analysis. Eur J Prev Cardiol. 2023;30(10):1028–38.CrossRefPubMed
35.
go back to reference Damanti S, Rossi PD, Cesari M. Orthostatic hypertension and adverse clinical outcomes in adults and older people. J Geriatr Cardiol. 2021;18(9):779–82.PubMedPubMedCentral Damanti S, Rossi PD, Cesari M. Orthostatic hypertension and adverse clinical outcomes in adults and older people. J Geriatr Cardiol. 2021;18(9):779–82.PubMedPubMedCentral
36.
go back to reference Toori MA, et al. Prevalence of hypercholesterolemia, high LDL, and low HDL in Iran: a systematic review and meta-analysis. Iran J Med Sci. 2018;43(5):449. Toori MA, et al. Prevalence of hypercholesterolemia, high LDL, and low HDL in Iran: a systematic review and meta-analysis. Iran J Med Sci. 2018;43(5):449.
37.
go back to reference Akbartabar Toori MP, et al. Prevalence of Hypercholesterolemia, high LDL, and Low HDL in Iran: a systematic review and Meta-analysis. Iran J Med Sci. 2018;43(5):449–65.PubMed Akbartabar Toori MP, et al. Prevalence of Hypercholesterolemia, high LDL, and Low HDL in Iran: a systematic review and Meta-analysis. Iran J Med Sci. 2018;43(5):449–65.PubMed
38.
go back to reference Tabatabaei-Malazy O, et al. Prevalence of dyslipidemia in Iran: a systematic review and meta-analysis study. Int J Prev Med. 2014;5(4):373.PubMedPubMedCentral Tabatabaei-Malazy O, et al. Prevalence of dyslipidemia in Iran: a systematic review and meta-analysis study. Int J Prev Med. 2014;5(4):373.PubMedPubMedCentral
Metadata
Title
Evaluation of the prevalence of cardiometabolic disorders (diabetes, hypertension, and hyperlipidemia) diagnosed, undiagnosed, treated, and treatment goal in the elderly: Bushehr Elderly Health Program (BEH)
Authors
Mahbube Ebrahimpur
Erfan Mohammadi-Vajari
Yasaman Sharifi
Leila Ghotbi
Masoumeh Sarvari
Aryan Ayati
Baran Hashemi
Zhaleh Shadman
Pouria Khashayar
Afshin Ostovar
Noushin Fahimfar
Gita Shafiee
Elnaz Shahmohamadi
Tahereh Yavari
Iraj Nabipour
Bagher Larijani
Moloud Payab
Farshad Sharifi
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2024
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-024-01561-0

Other articles of this Issue 1/2024

BMC Endocrine Disorders 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.